Fundraising FoxHatteras Venture Partners — 2025 Investments
6 investments dated 2025 · listed companies and verified rows first · show all
A biotech company offering gene expression analysis tools for blood-based biomarker detection across multiple cancer types.
BiotechDigital HealthMedical DevicesDurham, US
Charles M. Perou(Founder and Director)inMICHAEL MILBURN(Executive Officer, Director)inDavid Neil Hayes(Executive Officer, Director)
BoardArnold Levine(Director)
Board seatMyla Lai-GoldmanClay Thorp· per SEC Form D
Co-investorsIAG Capital Partners
Qoniq combines tailored AI analytics with expert guidance to help Medical Affairs and Scientific Affairs teams analyze large volumes of publications and datasets, surface patterns, and generate industry-standard, well-sourced scientific reports.
AI & Machine LearningBiotechHealthtechPalo Alto, US
Gregory Kostello(Executive Officer)Lana Feng(Executive Officer, Director)inSusan Shiff(Executive Officer, Director)inWilliam Dai(Director)
BoardAndrew Schwab(Director)
Board seatJohn Crumpler· per SEC Form D
Co-investorsFusionPharmStars VenturesRealization Capital PartnersSteelSky VenturesJLL Spark Global Venturesnoa
Altis Biosystems builds RepliGut®, human intestinal tissue models grown from human intestinal stem cells that provide human-relevant preclinical data for drug absorption, metabolism, toxicity, and disease modeling.
BiotechDeep TechHealthtechMedical DevicesDurham, US
Christopher Sims(Executive Officer)inJimmy Smedley(Executive Officer)inSamuel Franklin(Director)Joseph McMahon(Director)Michael Biron(Executive Officer, Director)
BoardChristopher Perkins(Director)
Co-investorsAtlanta Technology AngelsCentral Texas Angel NetworkCheckmate Capital Group LLCCowtown AngelsJohnson Venture PartnersNC IDEA+1 more
Incyclix Bio develops precision cancer treatments targeting the CDK family of enzymes to restore cell cycle control in tumors, including CDK targets beyond CDK4/6 such as CDK2.
BiotechHealthtechDurham, US
Patrick Roberts(Executive Officer and member of the Board of Managers.)in
BoardFredric N. Eshelman(Executive Officer and member of the Board of Managers.)Sid Subramony(Member of the Board of Managers.)Norman Sharpless(Member of the Board of Managers.)
Co-investorsCape Fear BioCapitalEshelman Ventures, LLCHatteras
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.